Metronidazol EQL Pharma approved

Report this content

The pharmaceutical Metronidazol EQL Pharma, tablets 200mg and 400mg, has been approved by the Swedish Medicine Products Agency.

Metronidazol EQL Pharma is a prescription drug used to treat infections caused by certain types of bacteria that live without oxygen (anaerobic bacteria). Metronidazol EQL Pharma is also used to treat infections caused by certain unicellular organisms (protozoa).

Metronidazol EQL Pharma contains metronidazole, a substance that has been registered in Sweden since 1980. Metronidazol EQL Pharma becomes the first and only generic available in Sweden in the strengths 200mg and 400mg. The market for metronidazole in these strengths is limited to approx. SEK 5.7 million in total annual sales in Sweden.

The product is expected to be launched during the fourth quarter, 2019.

For further information, please contact:
Christer Fåhraeus

CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

About EQL Pharma 
EQL Pharma AB is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently has 16 niche generics (i.e. generics with little or no competition except for the original medicine) approved on the Swedish and Danish markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2019 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma AB is based in Lund, Sweden, employs 8 people and is listed on Spotlight Stock Market. EQL Pharma AB also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China. 


Documents & Links